REVB.NASDAQRevelation Biosciences, INC
10-K/A: Revelation Biosciences Files Amended 10-K to Correct Certification Language
Sentiment:
Annual Report Amendment
Revelation Biosciences has filed an amendment to its annual report to correct an omission in the certifications of its principal executive and financial officers.
Capital raiseThe company plans to seek additional funding through public or private equity or debt financings.The company completed a public offering in February 2024, raising approximately $5.4 million in net proceeds.
Worse than expectedThe company has incurred recurring losses since its inception and has never generated revenue.The company's auditor has raised concerns about the company's ability to continue as a going concern.The company's net loss for 2023 was $0.1 million, which is worse than the $10.8 million loss in 2022.
Summary
- Revelation Biosciences filed an amendment to its original 10-K report for the fiscal year ended December 31, 2023, to include previously omitted language in the certifications of its CEO and CFO.
- The amendment does not reflect any events occurring after the original filing date or modify any other disclosures.
- The company's management has concluded that their disclosure controls and procedures were effective as of December 31, 2023.
- There were no material changes in internal control over financial reporting during the most recent quarter.
- The company's financial statements for 2023 and 2022 are included in the report, with an independent auditor's opinion stating they present fairly the company's financial position and results of operations.
- The auditor's report includes an explanatory paragraph regarding the company's ability to continue as a going concern due to recurring losses and no revenue sources.
- The company had cash and cash equivalents of $11.9 million as of December 31, 2023, and an accumulated deficit of $25.5 million.
- The company incurred a net loss of $0.1 million for the year ended December 31, 2023.
- The company has never generated revenue and does not expect to generate revenue from product sales for several years.
- The company plans to seek additional funding through public or private equity or debt financings.
Sentiment
Score: 3
Explanation: The document highlights significant financial challenges, including recurring losses, an accumulated deficit, and concerns about the company's ability to continue as a going concern. While the company has raised additional capital, the overall outlook is negative due to the lack of revenue and ongoing legal issues.
Positives
- The company's management has concluded that their disclosure controls and procedures were effective as of December 31, 2023.
- The company successfully completed a public offering in February 2024, raising approximately $5.4 million in net proceeds.
- The company has significant net operating loss carryforwards that could be used to offset future taxable income.
Negatives
- The company has incurred recurring losses since its inception, including a net loss of $0.1 million for the year ended December 31, 2023.
- The company has an accumulated deficit of $25.5 million as of December 31, 2023.
- The company has never generated revenue and does not expect to generate revenue from product sales for several years.
- The company's auditor has raised concerns about the company's ability to continue as a going concern.
- The company is involved in ongoing legal proceedings with LifeSci Capital LLC and A-IR Clinical Research Ltd.
Risks
- The company's ability to continue as a going concern is dependent on raising additional capital.
- The company may not be able to obtain financing on acceptable terms, or at all.
- The terms of any financing may adversely affect the holdings or the rights of the company's stockholders.
- The company is involved in ongoing legal proceedings that could result in significant liabilities.
- The company's research and development programs are subject to risks and uncertainties, and there is no guarantee of success.
- The company has never generated revenue and does not expect to generate revenue from product sales for several years.
Future Outlook
The company expects to continue to incur significant operating and net losses, as well as negative cash flows from operations, for the foreseeable future as it continues to complete all necessary product development or future commercialization efforts. The company plans to seek additional funding through public or private equity or debt financings.
Management Comments
- Management concluded that the company's disclosure controls and procedures were effective as of December 31, 2023.
- Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives.
Industry Context
The company operates in the biopharmaceutical industry, which is characterized by high research and development costs, long development timelines, and regulatory uncertainty. The company's focus on immunologic therapeutics and diagnostics is aligned with current trends in the industry.
Comparison to Industry Standards
- The company's financial performance is not directly comparable to established pharmaceutical companies with revenue-generating products.
- The company's reliance on external funding is typical for early-stage biopharmaceutical companies.
- The company's research and development expenses are consistent with other companies in the clinical-stage biopharmaceutical sector.
- The company's cash burn rate is a concern, as it is typical for companies in this sector to have high cash burn rates.
Legal Proceedings
- LifeSci Capital LLC filed an action against the company seeking damages of approximately $5.3 million plus interest for unpaid banking and advisory fees.
- A-IR Clinical Research Ltd. filed a claim against the company seeking £1.6 million in unpaid invoices, plus interest and costs, relating to the company's viral challenge study.
Stakeholder Impact
- Shareholders face the risk of dilution and potential loss of investment due to the company's need for additional capital.
- Employees may be impacted by potential delays or reductions in research and development programs.
- Customers and suppliers may be affected by the company's financial instability and potential inability to deliver products or services.
- Creditors face the risk of non-payment due to the company's financial challenges.
Next Steps
- The company plans to continue the development of GEM-SSI, GEM-AKI and GEM-CKD.
- The company plans to conduct a combined Phase 1a clinical study for GEM-SSI and GEM-AKI.
- The company plans to conduct a Phase 1b clinical study for GEM-SSI for the prevention of surgical site infection in colorectal surgery.
- The company plans to conduct a Phase 1b clinical study for GEM-AKI for the prevention and treatment of AKI due to cardiac surgery.
- The company plans to continue necessary preclinical work for GEM-CKD.
- The company plans to continue to develop other products and therapies.
- The company plans to fund working capital and general corporate purposes.
Key Dates
| Date | Description |
|---|---|
| 2019-11-20 | Revelation Biosciences, Inc. was incorporated in Delaware. |
| 2021-02-28 | Original lease agreement for laboratory space. |
| 2021-08-29 | Petra and Old Revelation signed the Business Combination Agreement. |
| 2022-01-04 | Revelation Sub entered into a convertible note with AXA. |
| 2022-01-06 | Old Revelation purchased Petra common stock with proceeds from the convertible note. |
| 2022-01-10 | The company consummated its business combination with Revelation Biosciences Sub, Inc. |
| 2022-01-25 | The company closed a private placement (PIPE Investment). |
| 2022-01-28 | The company filed a registration statement with the SEC on Form S-1. |
| 2022-02-07 | The registration statement on Form S-1 became effective. |
| 2022-02-18 | LifeSci Capital LLC filed an action against the company. |
| 2022-02-22 | The company received a notice of cash exercise for the Class A Pre-Funded Warrants. |
| 2022-07-28 | The company closed a public offering. |
| 2022-09-27 | A-IR Clinical Research Ltd. filed a claim against the company. |
| 2022-12-19 | The company closed the sale of one share of Series A Preferred Stock. |
| 2023-01-13 | The company's units were mandatorily separated. |
| 2023-01-22 | The company filed a Certificate of Amendment effecting a reverse stock split. |
| 2023-01-30 | The Series A Preferred Stock was automatically redeemed. |
| 2023-02-01 | The company effected a reverse stock split. |
| 2023-02-09 | The registration statement on Form S-1 was declared effective by the SEC. |
| 2023-02-13 | The company closed a public offering. |
| 2023-02-14 | The company received notices of cash exercise for the Class C Pre-Funded Warrants. |
| 2023-04-06 | The company received a notice of cash exercise for the Class C Pre-Funded Warrants. |
| 2023-04-18 | The company had until this date to regain compliance with Nasdaq listing rules. |
| 2023-07-14 | The company's 2023 Annual Meeting of Stockholders approved an amendment to the 2021 Equity Incentive Plan. |
| 2023-08-08 | The company received a letter from Nasdaq regarding noncompliance with minimum bid price. |
| 2023-12-01 | A Magistrate Judge issued a report recommending summary judgment in favor of LifeSci Capital LLC. |
| 2023-12-15 | The company filed objections to the Magistrate's report. |
| 2024-01-22 | The company filed a Certificate of Amendment effecting a reverse stock split. |
| 2024-01-25 | The company effected a reverse stock split. |
| 2024-01-31 | The registration statement on Form S-1 was declared effective by the SEC. |
| 2024-02-05 | The company closed a public offering. |
| 2024-02-08 | The company received a formal notice from Nasdaq stating that the company regained compliance with the minimum bid price requirement. |
| 2024-02-29 | Subsequent event date. |
| 2024-03-18 | The company received notices of cash exercises for the Class D Pre-Funded Warrants. |
| 2024-03-22 | The original 10-K was filed with the SEC. |
| 2024-09-23 | The amended 10-K/A was filed with the SEC. |
Keywords
biopharmaceutical, immunologic therapeutics, diagnostics, clinical-stage, financial statements, going concern, warrants, stock options, public offering, net loss, operating expenses, research and development, internal control, disclosure controls, Sarbanes-Oxley Act
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.